Long-acting injectable risperidone for the treatment of schizophrenia: clinical perspectives.
about
Q24197685Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia.Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece.Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and cost-effectiveness.Advances in recombinant DNA technology: corifollitropin alfa, a hybrid molecule with sustained follicle-stimulating activity and reduced injection frequency.Long-acting atypical injectable antipsychotics in the treatment of schizophrenia: safety and tolerability review.Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes.Clinical implications of exenatide as a twice-daily or once-weekly therapy for type 2 diabetes.Evaluating appropriateness of prescribing of long-acting risperidone for injection in acute care settings.A review of paliperidone palmitate.Incidence and time course of extrapyramidal symptoms with oral and long-acting injectable paliperidone: a posthoc pooled analysis of seven randomized controlled studies.Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection.A 12-week intramuscular toxicity study of risperidone-loaded microspheres in Beagle dogs.The need for efficient long-term neuroleptic treatment in schizophrenic patients and the place of long acting injectable antipsychotics.Possible long-acting risperidone-induced hypothermia precipitating phenytoin toxicity in an elderly patient.Overweight induced by chronic risperidone exposure is correlated with overexpression of the SREBP-1c and FAS genes in mouse liver.
P2860
Q24197685-C9869291-4B1F-4254-B2C4-09F4D91CD106Q35143555-1FB8EE28-975C-41DF-9762-6FE580512AC8Q36198389-B0AD42E7-CAED-46CF-8B4B-A03F0E9A7291Q37356486-279368C9-CC44-4C2B-8A13-C42672707F83Q37381361-BE735AA3-8229-4EEC-801D-8F8AAECC814CQ37778398-FE69F352-8510-4C1D-AF17-00049BE7E674Q37900626-BA790A17-9385-4126-ABE3-B3780262BCF9Q37929511-CD1D07F6-C36D-48F1-B3C2-7EDFD57F05DDQ38000246-6203EAD8-F4C0-4E1B-BD36-E2E8FBF673FFQ38067137-F712E7D1-33F3-48C0-8F57-D67317E4F105Q41862402-11D4F186-E323-45B4-85A5-30B46215FA30Q42279135-BBD3A961-1D87-4E65-B835-2175947A4BD8Q45249478-3E58B77D-905D-44E8-AD71-DD99CD4C4993Q45772838-F0F5D760-48DF-4A4E-A61D-6AD6EAF23DFEQ50803501-672AED99-CACA-44E8-B0B9-863F4A1C4A27Q51502306-15F452CE-880B-4683-8725-3B437B3475CF
P2860
Long-acting injectable risperidone for the treatment of schizophrenia: clinical perspectives.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Long-acting injectable risperi ...... hrenia: clinical perspectives.
@en
type
label
Long-acting injectable risperi ...... hrenia: clinical perspectives.
@en
prefLabel
Long-acting injectable risperi ...... hrenia: clinical perspectives.
@en
P1433
P1476
Long-acting injectable risperi ...... hrenia: clinical perspectives.
@en
P2093
Hans-Jürgen Möller
P304
P356
10.2165/00003495-200767110-00003
P577
2007-01-01T00:00:00Z
P6179
1053679805